Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Urothelial Carcinoma Urethra clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07951060
LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency
This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma. LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug. The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics. The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment. All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-20
NCT06983210
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used when metastasis has already occurred at diagnosis and surgery is not curative (metastatic urothelial carcinoma) or when the cancer recurs after local therapy such as surgery or radiation therapy (recurrent urothelial carcinoma). Although there are several recommended treatments for urothelial carcinoma, the options are often limited by side effects and other factors, and these treatments may not be fully effective. Therefore, the development of safer and more effective treatments is desired. 【About the Drugs to be Used in this Clinical Trial】 In this clinical trial, the investigational drug MIKE-1 will be used in combination with nivolumab plus GC (cisplatin gemcitabine), one of the recommended chemotherapy regimens, and subsequently with nivolumab monotherapy for patients with unresectable metastatic or recurrent urothelial cancer. Nivolumab, cisplatin, and gemcitabine are injectable (intravenous infusion), while MIKE-1 is oral. 【Purpose of the Clinical Trial】 The purpose of this clinical trial is to evaluate the efficacy (how much the cancer shrinks or slows down) and safety of the investigational drug MIKE-1 in combination with nivolumab and gemcitabine and cisplatin therapy in patients with untreated unresectable or recurrent urothelial cancer.
Gender: All
Ages: 18 Years - 79 Years
Updated: 2025-08-14
1 state